Viskase Holdings, Inc. balance sheet VISK

Annual Quarterly

As of Sep 30, 2026, Viskase Holdings, Inc. had total assets of $427.5 million. Total assets were up 878.3% from a year earlier. Stockholders' equity was $178.9 million. It held $7.7 million in cash and investments against $290.6 million of total debt, net debt of $282.9 million. The current ratio, current assets divided by current liabilities, was 1.07.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

Line	FY 2026 Sep 30, 2026	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019	FY 2018 Dec 31, 2018	FY 2017 Dec 31, 2017	FY 2016 Dec 31, 2016
Assets
Cash	8 -82.1%	43 -9.1%	47 -0.3%	47 +0.1%	47 -1.4%	48 -1.0%	48 +784.0%	5 -16.2%	6 -13.1%	7 -2.1%	8 -34.6%
Cash and investments	8 -82.1%	43 -9.1%	47 -0.3%	47 +0.1%	47 -1.4%	48 -1.0%	48 +784.0%	5 -16.2%	6 -13.1%	7 -2.1%	8 -34.6%
Receivables	70	—	—	—	—	—	—	—	—	—	—
Inventory	100	—	—	—	—	—	—	—	—	—	—
Total current assets	226 +418.3%	43 -9.2%	47 -0.4%	47 -0.1%	47	—	48 +704.8%	6 -58.8%	15 +92.0%	8 -4.3%	8 -32.9%
Property and equipment, net	156	—	—	—	—	—	—	—	—	—	—
Goodwill	3	—	—	—	—	—	—	—	—	—	—
Total assets	427 +878.3%	43 -9.2%	47 -1.1%	48 +0.2%	48 -0.3%	48 -1.0%	48 +644.6%	6 -58.2%	16 +63.1%	10 -15.6%	11 -50.8%
Liabilities and equity
Accounts payable	43 +12876.4%	0 +0.0%	0 +0.0%	0 +0.0%	0 +0.0%	0 +9.6%	0 -6.8%	0 -26.2%	0 +95.1%	0 -70.8%	1 +755.6%
Total current liabilities	211 +38923.9%	1 -56.4%	2 -2.1%	2 +0.9%	2 +321.6%	0 -2.2%	0 -2.6%	0 -18.2%	1 +40.5%	0 -60.9%	1 -80.4%
Stockholders' equity	179 +19487.2%	-3 -183.9%	3 +185.8%	-4 -202.9%	3 -30.0%	5 -33.9%	7 +21.6%	6 -59.6%	15 +64.0%	9 -11.5%	10 -42.9%
Debt
Debt due within a year	136	—	—	—	—	—	—	—	—	—	—
Long-term debt	136	—	—	—	—	—	—	—	—	—	—
Lease liabilities	19	—	—	—	—	—	—	—	—	—	—
Total debt	291	—	—	—	—	—	—	—	—	—	—
Net cash	-283	—	—	—	—	—	—	—	—	—	—
Ratios
Current ratio	1.07x	58.57x	28.10x	27.62x	27.89x	—	117.07x	14.17x	28.12x	20.58x	8.41x
Debt to equity	1.62x	—	—	—	—	—	—	—	—	—	—
Return on equity	14.11%	—	25.86%	—	-5.46%	-9.63%	-17.81%	-16.17%	39.01%	59.55%	-10.90%
Return on assets	5.91%	-7.96%	1.65%	2.88%	-0.39%	-0.98%	-2.72%	-15.11%	37.71%	57.24%	-9.99%
Book value per share	12.49	-0.38	0.04	-0.05	0.05	0.07	0.10	0.14	0.34	0.21	0.23

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. The first column is the latest balance sheet when it is newer than the latest fiscal year. More on our methodology.

Company profile

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as: VISK (OTC)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Lombard, IL
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 727510
Former names: ENZON PHARMACEUTICALS, INC. (until Mar 25, 2026); ENZON PHARMACEUTICALS INC (until Feb 23, 2016); ENZON PHARMACEUTICALS INC (until Mar 22, 2006); ENZON PHARMACEUTICAL INC (until Dec 10, 2002); ENZON INC (until Dec 9, 2002)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.